AR039461A1 - COMBINED VACCINES INCLUDING IMMUNOGENIC CAMP AND GAPC FACTOR POLYPEPTIDES - Google Patents
COMBINED VACCINES INCLUDING IMMUNOGENIC CAMP AND GAPC FACTOR POLYPEPTIDESInfo
- Publication number
- AR039461A1 AR039461A1 ARP030101453A ARP030101453A AR039461A1 AR 039461 A1 AR039461 A1 AR 039461A1 AR P030101453 A ARP030101453 A AR P030101453A AR P030101453 A ARP030101453 A AR P030101453A AR 039461 A1 AR039461 A1 AR 039461A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- acid sequence
- gapc
- inclusive
- seq
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 101150093511 GAPC gene Proteins 0.000 title 1
- 101150115724 GAPC1 gene Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 17
- 102000004169 proteins and genes Human genes 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 241000193985 Streptococcus agalactiae Species 0.000 abstract 2
- 241000194042 Streptococcus dysgalactiae Species 0.000 abstract 2
- 241000194055 Streptococcus parauberis Species 0.000 abstract 2
- 241000194054 Streptococcus uberis Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 241000194056 Streptococcus iniae Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 208000004396 mastitis Diseases 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 abstract 1
- 229940115922 streptococcus uberis Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Uso de proteínas de unión a plasmina GapC de Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis) y Streptococcus iniae (S. iniae) en combinación con factores CAMP para prevenir o tratar infecciones bacterianas en general y mastitis en particular. Reivindicación 1: Una composición de vacuna, caracterizada porque comprende (a) un vehículo aceptable para uso farmacéutico; (b) un polipéptido del factor quimérico CAMP que comprende una secuencia de aminoácidos que presenta al menos un 80% de secuencia con la secuencia de aminoácidos contigua representada en las posiciones 27-314 de la figura 29; y (c) una proteína GapC, donde dicha proteína Gapc se selecciona del grupo formado por: (i) una proteína GapC que comprende una secuencia de aminoácidos con al menos un 80% de identidad de secuencia con la secuencia de aminoácidos que se muestra en las posiciones de aminoácidos 1 a 336, inclusive, de las figuras 1A-1B (SEQ ID N°: 4); (ii) una proteína GapC que comprende una secuencia de aminoácidos con al menos un 80% de identidad de secuencia con la secuencia de aminoácidos que se muestra en las posiciones de aminoácido 1 a 336, inclusive, de las figuras 2A-2B (SEQ ID N°: 6); (iii) una proteína GapC que comprende una secuencia de aminoácidos con al menos un 80% de identidad de secuencia con la secuencia de aminoácidos que se muestra en las posiciones de aminoácido 1 a 336, inclusive, de las figuras 3A-3B (SEQ ID N°: 8); (iv) una proteína GapC que comprende una secuencia de aminoácidos con al menos un 80% de identidad de secuencia con la secuencia de aminoácidos que se muestra en las posiciones de aminoácido 1 a 336, inclusive, de las figuras 4A-4B (SEQ ID N°: 10); (v) una proteína GapC que comprende una secuencia de aminoácidos con al menos un 80% de identidad de secuencia con la secuencia de aminoácidos que se muestra en las posiciones de aminoácido 1 a 336, inclusive, de las figuras 5A-5B (SEQ ID N°: 12); (vi) fragmentos inmunogénicos de (i), (ii), (iii), (iv), (v) y (vi), comprendiendo dichos fragmentos al menos 5 aminoácidos aproximadamente.Use of GapC plasmin-binding proteins of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis) and Streptococcus iniae (en paraee) in combination. with CAMP factors to prevent or treat bacterial infections in general and mastitis in particular. Claim 1: A vaccine composition, characterized in that it comprises (a) a vehicle acceptable for pharmaceutical use; (b) a CAMP chimeric factor polypeptide comprising an amino acid sequence having at least 80% sequence with the contiguous amino acid sequence depicted at positions 27-314 of Figure 29; and (c) a GapC protein, wherein said Gapc protein is selected from the group consisting of: (i) a GapC protein comprising an amino acid sequence with at least 80% sequence identity with the amino acid sequence shown in amino acid positions 1 to 336, inclusive, of Figures 1A-1B (SEQ ID N °: 4); (ii) a GapC protein comprising an amino acid sequence with at least 80% sequence identity with the amino acid sequence shown in amino acid positions 1 to 336, inclusive, of Figures 2A-2B (SEQ ID N °: 6); (iii) a GapC protein comprising an amino acid sequence with at least 80% sequence identity with the amino acid sequence shown in amino acid positions 1 through 336, inclusive, of Figures 3A-3B (SEQ ID N °: 8); (iv) a GapC protein comprising an amino acid sequence with at least 80% sequence identity with the amino acid sequence shown in amino acid positions 1 to 336, inclusive, of Figures 4A-4B (SEQ ID N °: 10); (v) a GapC protein comprising an amino acid sequence with at least 80% sequence identity with the amino acid sequence shown in amino acid positions 1 through 336, inclusive, of Figures 5A-5B (SEQ ID N °: 12); (vi) immunogenic fragments of (i), (ii), (iii), (iv), (v) and (vi), said fragments comprising at least approximately 5 amino acids.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21102200P | 2000-06-12 | 2000-06-12 | |
| US09/878,781 US6866855B2 (en) | 2000-06-12 | 2001-06-11 | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| US10/134,297 US6833134B2 (en) | 2000-06-12 | 2002-04-26 | Immunization of dairy cattle with GapC protein against Streptococcus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039461A1 true AR039461A1 (en) | 2005-02-23 |
Family
ID=34527709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101453A AR039461A1 (en) | 2000-06-12 | 2003-04-28 | COMBINED VACCINES INCLUDING IMMUNOGENIC CAMP AND GAPC FACTOR POLYPEPTIDES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR039461A1 (en) |
-
2003
- 2003-04-28 AR ARP030101453A patent/AR039461A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002113920A (en) | ANTIGENIC PEPTIDES NEISSERIA | |
| AR018603A1 (en) | A PEPTIDE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF ALZHEIMER'S DISEASE AND THE DOWN SYNDROME, PHARMACEUTICAL COMPOSITIONS AND VACCINES WHICH LOCATE, THE USE OF SUCH PEPTIDE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS OF DNA, SECTION A PLASMID OR VECTOR VI | |
| NZ551802A (en) | A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof | |
| AR008727A1 (en) | COMPOSITIONS AND MELTING PROTEINS INCLUDING A POLYPEPTIDE INCLUDING AN IMMUNOGENIC PORTION OF A PROSTATE PROTEIN OR ITS VARIANT, AND USES THEREOF TO PREPARE A MEDICINAL PRODUCT | |
| PE20071063A1 (en) | STABLE PROTEIN FORMULATIONS | |
| BR0208874A (en) | Surface proteins of streptococcus pyogenes | |
| RU2001134170A (en) | NEISSERIA Antigenic Peptides | |
| WO2003065973A8 (en) | Multivalent streptococcal vaccine compositions and methods for use | |
| DK1349944T3 (en) | Latency-associated peptide of TGF-beta to confer latency to pharmaceutically active proteins | |
| WO2001081380A3 (en) | Immunogenic pneumococcal protein and vaccine compositions thereof | |
| AR035077A1 (en) | VARIOUS NEUBLASTIN POLYPEPTIDES, FUSION PROTEINS, NUCLEIC ACIDS, VECTORS, HOSPED CELLS, METHODS TO PRODUCE SUCH POLYPEPTIDES, DIMERES, CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND USE OF THESE MEDICINES | |
| BR9812240A (en) | Altered g protein or rsv polypeptide, use of it, nucleic acid molecule encoding an altered g protein or rsv polypeptide, nucleic acid construction, recombinant host cell, processes of producing an altered g protein or rsv polypeptide immunogenic composition , to induce an immune response in a vertebrate, to inhibit the induction of disease increase after vaccination and subsequent infection of a vertebrate with rsv and to immunize a vertebrate against rsv, vaccine composition, vaccine, and, composition immunogenic | |
| WO2001096379A3 (en) | Immunization of dairy cattle with chimeric gapc protein against streptococcus infection | |
| EP0369816A3 (en) | Monoclonal antibodies specific for human polymorphic epithelial mucin | |
| AR039461A1 (en) | COMBINED VACCINES INCLUDING IMMUNOGENIC CAMP AND GAPC FACTOR POLYPEPTIDES | |
| US20020081304A1 (en) | Type f botulinum toxin and use thereof | |
| AR030292A1 (en) | A GAPC PROTEIN; YOUR PRODUCTION METHOD AND ITS USE; AN ISOLATED POLINUCLEOTIDE AND ITS USE; A RECOMBINING VECTOR; A CELL GUEST; A VACCINE COMPOSITION AND ITS PRODUCTION METHOD; ANTIBODIES AND THEIR USES; AND AN IMMUNODIAGNOSTIC KIT | |
| BR0012740A (en) | Compounds for the treatment of infectious and immune system disorders and methods for their use | |
| TH57274B (en) | Cattle Milk Immunization with GapC Protein Against Infection Streptococcus | |
| WO2023196634A3 (en) | Vaccines and related methods | |
| ATE305941T1 (en) | VACCINE | |
| AR030293A1 (en) | A VACCINE COMPOSITION THAT INCLUDES AN FC RECEIVING PROTEIN; A METHOD TO PREPARE IT; USE OF SUCH PROTEIN AND A POLINUCLEOTIDE THAT CODIFIES FOR SUCH PROTEIN AND A METHOD TO TREAT OR PREVENT A BACTERIAL INFECTION | |
| AR025198A1 (en) | COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISORDERS AND THE IMMUNE SYSTEM AND METHODS FOR USE | |
| WO2002000821A3 (en) | A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide | |
| WO2001075050A3 (en) | A novel polypeptide, a human membrane vesicle transport relative protein 9 and the polynucleotide encoding the polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |